Given that both VEGFR2 and HIF-1α are key regulators of tumor angiogenic processes, dual targeting of the two angiogenic pathway axes would provide more effective therapeutic potential for the treatment of hypervascularized tumors [25,26]. This evidence concerns the gene HIF1A and neoplasm.